|Other author/creator||Olson, Steve, 1956-|
|Other author/creator||Robinson, Sally.|
|Other author/creator||Giffin, Robert B.|
|Other author/creator||Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation.|
||Introduction -- Overview Of key issues -- Cardiac safety biomarkers -- Assessing and predicting kidney safety -- Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials -- Future considerations.
||"Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."
|Bibliography note||Includes bibliographical references.|
|Source of description||Print version record.|
|Issued in other form||Print version: Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation. Accelerating the development of biomarkers for drug safety. Washington, D.C. : National Academies Press, ©2009 9780309131247|
|ISBN||9780309131254 (electronic bk.)|
|ISBN||0309131251 (electronic bk.)|